Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF Challenge Study in Healthy Adults
NCT04785612Phase 2Completed
- Sponsor
- hVIVO
- Start
- Nov 2020
- Primary completion
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing RSVPreF with Placebo (2 arms). Primary endpoints: Area Under the Viral Load-time Curve (VL-AUC) of RSV, Number of Participants With RT-PCR Confirmed (Detected) Incidence of Symptomatic Infection and 1 more. Started Nov 2020; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04785612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785612.